API | voretigene neparvovec

voretigene neparvovec (Luxturna) Report issue

Gene therapy Orphan Drug ^FDA Approved ^FDA Breakthrough Therapy ^FDA

AACT

Active Ingredient History

NOW

Voretigene neparvovec, sold under the brand name Luxturna, is a gene therapy medication for the treatment of Leber congenital amaurosis. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
voretigene neparvovec

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

aav2-hrpe65v2 | raav2-hrpe65

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (1)

Retinal Diseases (approved 2017)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Leber Congenital Amaurosis (Phase 3)

Mutation (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue